Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420345 | 1.00 | TBXAS1 (0.56) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL11059401 | 0.90 | TBXAS1 (0.71) | TBXAS1LMNAALDH1A1CYP3A4 | |
| SCHEMBL2370955 | 0.87 | ALDH1A1 (0.48) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL7345369 | 0.86 | MMP8 (0.52) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL16508902 | 0.86 | TBXAS1 (0.57) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL27224527 | 0.85 | TBXAS1 (0.47) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL18039180 | 0.85 | CYP1A2 (0.50) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL30178278 | 0.84 | FDPS (0.48) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL21947585 | 0.84 | FDPS (0.48) | TBXAS1LMNAFDPSKMT2APKM | |
| SCHEMBL20543866 | 0.84 | FDPS (0.48) | TBXAS1LMNAFDPSKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | PAM, CHRM3, AZI2 | TBXAS1 3935/4885LMNA 3815/4885FDPS 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.